Arbaclofen Given a Second Chance by the Simons Foundation
Light at the end of the tunnel, for some I did recently write about autism drugs that target the GABA B receptor. Western doctors have Baclofen and a few did have experimental use of the more potent version called Arbaclofen, or R-Baclofen. We saw that Russian doctors have a wider choice. The rights to use Arbaclofen have been acquired by the Simons Foundation , and they intend to restart autism trials in humans. Mouse studies support second chance for fragile X drug Arbaclofen was found to be effective in some people with Fragile-X and autism, but it failed its clinical trial and the developer, Seaside Therapeutics, went out of business. The Simons Foundation , for those who do not know, is probably the best thing to ever happen to people with autism. The founder of the foundation is an American multi-billionaire, former fund manager and mathematician. He has a daughter with autism and decided to do something about it. Having already funded...